Chemists at Oregon State University have discovered and synthesized a new compound that in laboratory and animal tests appears to be similar to, but may have advantages over one of the most important antidepressant medications in the world. A patent has been applied for on the compound, and findings on it published in the Journal of Medicinal Chemistry. Continued animal studies and eventually, human clinical trials will be necessary before the compound could be approved for human medical use, researchers say. "Based on our results so far, this promises to be one of the most effective antidepressants yet developed, " said James White, a professor emeritus of chemistry at OSU.
Even with the best of available treatments, over a third of patients with depression may not achieve a satisfactory antidepressant response. Deep brain stimulation (DBS), a form of targeted electrical stimulation in the brain via implanted electrodes, is now undergoing careful testing to determine whether it could play a role in the treatment of patients who have not sufficiently improved during more traditional forms of treatment. A major challenge of this work is determining the best region of the brain to stimulate. Some researchers stimulate the subgenual prefrontal cortex, a brain region implicated in depressed mood states, while others stimulate a region called the "anterior limb of the internal capsule", a nerve pathway that passes through the basal ganglia, a lower brain region.
Depression affects mind, body and behavior. Genetic factors, food allergies, child birth, obesity, pre menstrual syndrome, menopause, Folic acid deficiency and obesity can cause depression. Antidepressant medications are available to treat the condition, but they may cause some side effects like dry mouth, sedation, blurry vision, constipation, memory loss or insomnia. If the person does not respond well to the medications or experience side effects, it is then advisable to choose depression alternative treatment. Aromatherapy can help to treat mild forms of depression. Basil, cedar wood, lavender, lemon, rose, sandalwood and jasmine are some of the essential oils used to treat depression.
"Why are adults so cranky" ask the children in a seminar recently? By the time many people reach middle age, they are often not the cheerful, hopeful happy beings they once were as children. What happens that there are so many people suffering from depression, that you can actually find traces of anti-depressant medication in some of our drinking water? When we are children, generally we have many positive experiences and so we are cheerful, feel good and are happy a lot of the time. As life continues, we begin to experience more contrast or negative events in our life and we begin to focus more on them, than we focus on where we are headed and what we are hoping for.
Depression among children and adolescents has been on the rise for some time, but has only been taken seriously in the last twenty to thirty years. While it is normal for young people to experience mood swings or sad days, clinically depressed youths may represent as much as five percent of the population. Improved diagnostic techniques and parental awareness have helped to expose this problem, and open the doors for more children to receive psychiatric treatment of childhood depression. Unfortunately there is no single cause that has been identified for depression. It is known that there is a higher occurrence within specific families, supporting the idea that genetics might be a factor contributing to the biochemical causes of this serious illness.
BENEFITS OF ICS FOR COPD MAY BE OVERSTATED Inhaled corticosteroids (ICS) are widely used for the treatment of chronic obstructive pulmonary disease (COPD). However, new research suggests that ICS may only provide a modest benefit in reducing exacerbations in patients with COPD. Researchers from India conducted a metaanalysis of 11 studies (8, 164 patients) that reported the efficacy of ICS versus placebo in prevention of COPD exacerbations. The use of ICS was associated with a modest reduction in the occurrence of exacerbations, with a subgroup analysis revealing only a benefit in patients with a FEV1 less than 50 percent. Upon further analysis using metaregression, the researchers found no demonstrable linear relationship between the efficacy of ICS and prevention of COPD exacerbation that was related to the level of stable lung function.